142 related articles for article (PubMed ID: 34711364)
1. The Extrapolation Performance of Survival Models for Data With a Cure Fraction: A Simulation Study.
Kearns B; Stevenson MD; Triantafyllopoulos K; Manca A
Value Health; 2021 Nov; 24(11):1634-1642. PubMed ID: 34711364
[TBL] [Abstract][Full Text] [Related]
2. Comparing current and emerging practice models for the extrapolation of survival data: a simulation study and case-study.
Kearns B; Stevenson MD; Triantafyllopoulos K; Manca A
BMC Med Res Methodol; 2021 Nov; 21(1):263. PubMed ID: 34837957
[TBL] [Abstract][Full Text] [Related]
3. Survival Extrapolation Incorporating General Population Mortality Using Excess Hazard and Cure Models: A Tutorial.
Sweeting MJ; Rutherford MJ; Jackson D; Lee S; Latimer NR; Hettle R; Lambert PC
Med Decis Making; 2023 Aug; 43(6):737-748. PubMed ID: 37448102
[TBL] [Abstract][Full Text] [Related]
4. A Case Study Examining the Usefulness of Cure Modelling for the Prediction of Survival Based on Data Maturity.
Grant TS; Burns D; Kiff C; Lee D
Pharmacoeconomics; 2020 Apr; 38(4):385-395. PubMed ID: 31848900
[TBL] [Abstract][Full Text] [Related]
5. Cure fraction estimation from the mixture cure models for grouped survival data.
Yu B; Tiwari RC; Cronin KA; Feuer EJ
Stat Med; 2004 Jun; 23(11):1733-47. PubMed ID: 15160405
[TBL] [Abstract][Full Text] [Related]
6. Dynamic and Flexible Survival Models for Extrapolation of Relative Survival: A Case Study and Simulation Study.
Kearns B; Stevenson MD; Triantafyllopoulos K; Manca A
Med Decis Making; 2022 Oct; 42(7):945-955. PubMed ID: 35769004
[TBL] [Abstract][Full Text] [Related]
7. Predicting Survival for Chimeric Antigen Receptor T-Cell Therapy: A Validation of Survival Models Using Follow-Up Data From ZUMA-1.
Vadgama S; Mann J; Bashir Z; Spooner C; Collins GP; Bullement A
Value Health; 2022 Jun; 25(6):1010-1017. PubMed ID: 35667774
[TBL] [Abstract][Full Text] [Related]
8. Generalized Linear Models for Flexible Parametric Modeling of the Hazard Function.
Kearns B; Stevenson MD; Triantafyllopoulos K; Manca A
Med Decis Making; 2019 Oct; 39(7):867-878. PubMed ID: 31556792
[No Abstract] [Full Text] [Related]
9. Impact of limited sample size and follow-up on single event survival extrapolation for health technology assessment: a simulation study.
Beca JM; Chan KKW; Naimark DMJ; Pechlivanoglou P
BMC Med Res Methodol; 2021 Dec; 21(1):282. PubMed ID: 34922454
[TBL] [Abstract][Full Text] [Related]
10. Bayesian pairwise meta-analysis of time-to-event outcomes in the presence of non-proportional hazards: A simulation study of flexible parametric, piecewise exponential and fractional polynomial models.
Freeman SC; Sutton AJ; Cooper NJ; Gasparini A; Crowther MJ; Hawkins N
Res Synth Methods; 2024 May; ():. PubMed ID: 38772906
[TBL] [Abstract][Full Text] [Related]
11. Extrapolation of Survival Curves Using Standard Parametric Models and Flexible Parametric Spline Models: Comparisons in Large Registry Cohorts with Advanced Cancer.
Gray J; Sullivan T; Latimer NR; Salter A; Sorich MJ; Ward RL; Karnon J
Med Decis Making; 2021 Feb; 41(2):179-193. PubMed ID: 33349137
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of survival extrapolation in immuno-oncology using multiple pre-planned data cuts: learnings to aid in model selection.
Bullement A; Willis A; Amin A; Schlichting M; Hatswell AJ; Bharmal M
BMC Med Res Methodol; 2020 May; 20(1):103. PubMed ID: 32375680
[TBL] [Abstract][Full Text] [Related]
13. Impact of Extrapolation Model Choices on the Structural Uncertainty in Economic Evaluations for Cancer Immunotherapy: A Case Study of Checkmate 067.
Shao T; Zhao M; Liang L; Shi L; Tang W
Pharmacoecon Open; 2023 May; 7(3):383-392. PubMed ID: 36757569
[TBL] [Abstract][Full Text] [Related]
14. Current estimates of the cure fraction: a feasibility study of statistical cure for breast and colorectal cancer.
Stedman MR; Feuer EJ; Mariotto AB
J Natl Cancer Inst Monogr; 2014 Nov; 2014(49):244-54. PubMed ID: 25417238
[TBL] [Abstract][Full Text] [Related]
15. Survival Extrapolation in Cancer Immunotherapy: A Validation-Based Case Study.
Bullement A; Latimer NR; Bell Gorrod H
Value Health; 2019 Mar; 22(3):276-283. PubMed ID: 30832965
[TBL] [Abstract][Full Text] [Related]
16. Assessing the Performance of Alternative Methods for Estimating Long-Term Survival Benefit of Immuno-oncology Therapies.
Monnickendam G
Value Health; 2024 Jun; 27(6):746-754. PubMed ID: 38428815
[TBL] [Abstract][Full Text] [Related]
17. Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival Extrapolations.
Ouwens MJNM; Mukhopadhyay P; Zhang Y; Huang M; Latimer N; Briggs A
Pharmacoeconomics; 2019 Sep; 37(9):1129-1138. PubMed ID: 31102143
[TBL] [Abstract][Full Text] [Related]
18. Estimating and modelling cure in population-based cancer studies within the framework of flexible parametric survival models.
Andersson TM; Dickman PW; Eloranta S; Lambert PC
BMC Med Res Methodol; 2011 Jun; 11():96. PubMed ID: 21696598
[TBL] [Abstract][Full Text] [Related]
19. How accurate are the longer-term projections of overall survival for cancer immunotherapy for standard versus more flexible parametric extrapolation methods?
Cooper M; Smith S; Williams T; Aguiar-Ibáñez R
J Med Econ; 2022; 25(1):260-273. PubMed ID: 35060433
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Flexible Parametric Relative Survival Approaches for Enforcing Long-Term Constraints When Extrapolating All-Cause Survival.
Lee S; Lambert PC; Sweeting MJ; Latimer NR; Rutherford MJ
Value Health; 2024 Jan; 27(1):51-60. PubMed ID: 37858887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
